Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19898261 | 1.00 | BTK (0.42) | BTKKMT2AKDM1AMAOBEPHX1 | |
| SCHEMBL19898893 | 1.00 | BTK (0.42) | BTKKMT2AKDM1AMAOBEPHX1 | |
| SCHEMBL19898977 | 0.85 | BTK (0.45) | BTKKMT2AKDM1AMAOBEPHX1 | |
| SCHEMBL12528145 | 0.79 | BTK (0.46) | BTKKMT2AKDM1AMAOBEPHX1 | |
| SCHEMBL4778890 | 0.79 | BTK (0.46) | BTKKMT2AKDM1AMAOBEPHX1 | |
| SCHEMBL30772643 | 0.79 | BTK (0.46) | BTKKMT2AKDM1AMAOBEPHX1 | |
| SCHEMBL603316 | 0.79 | BTK (0.46) | BTKKMT2AKDM1AMAOBEPHX1 | |
| SCHEMBL12527395 | 0.79 | BTK (0.46) | BTKKMT2AKDM1AMAOBEPHX1 | |
| SCHEMBL603315 | 0.79 | BTK (0.46) | BTKKMT2AKDM1AMAOBEPHX1 | |
| SCHEMBL19898629 | 0.79 | BTK (0.46) | BTKKMT2AKDM1AMAOBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ARQULE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3504213-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018039310-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | BTK, SYK, LCK | BTK 1/4885KMT2A 2325/4885KDM1A 1485/4885 |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | BTK, SYK, LCK | BTK 1/4885KMT2A 2325/4885KDM1A 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.